Announced
Completed
Synopsis
Alternative asset managers CPE and Mirae Asset led a $100m Series B round in JW Therapeutics, a developer of cell-based therapy technologies. The round saw the participation of Chinese state-backed investment firm Oriza Holdings and CR-CP Life Science Fund, a 50-50 joint venture between China Resources Group and Thai conglomerate Charoen Pokphand Group, existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec. "We are very pleased to welcome our new investors and, by working together, we hope to accelerate our product development and serve Chinese Patients,” James Li, JW Therapeutics Co-Founder and CEO.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.